Bruker is a performace leader in preclinical imaging instrumentation. Bruker offers nine imaging modalities: PET, SPECT, CT, MRI, MPI, fluorescence, luminiscence, radioisotipic imaging and X-ray.
Discover
Back to filter
Show all topics (10)
Related topics
WEBINAR: Recent Advancements In Neurodegenerative Biomarkers
Sep 6, 2021
Recent Advancements in Neurodegenerative Biomarkers: Progress Towards a Diagnostic Blood Test for Alzheimer’s Disease
How to Improve Your Viral Nucleic Acid Extraction Processes
Sep 6, 2021
High-Throughput Extraction with CyBio FeliX
Introducing New Aura 4.0 software
Aug 31, 2021
With new features for both acquisition & analysis Aura Software enables you to capture and analyze your data quickly,...
Comparison of gamma and x-ray irradiation results
Aug 12, 2021
Biological effects of Cs-137 and X-ray irradiators are comparable with regards to...
Hypoxia further exacerbates myopathy in broilers via alteration of satellite cell fate
Aug 2, 2021
Woody breast (WB) condition has created a variety of challenges for the global poultry...
High quality Bioluminescence and X-Ray analysis in lung squamous cell carcinoma
Jul 21, 2021
Spectral Instruments Imaging provides unrivaled sensitivity for bioluminescence,...
Top 10 Pharma companies have chosen CYTEK for their flow cytometry facility
Jul 15, 2021
6 of Top 10 Pharma Companies (Based on total group revenues) have chosen CYTEK - full...
ACCELA webinar recording : IntraVital Microscopy (IVM): In Vivo Live Cell Imaging Platform
Jul 15, 2021
Intravital microscopy can visualize...
Webinar recording: Autofluorescence management - the power of Spectral Flow Cytometry
Jul 15, 2021
One of the key advantages of spectral flow cytometry is its ability to extract sample...
Webinar recording: Super-Resolution imaging of Chromatin organization in health and disease
Jul 9, 2021
Understanding how cells organize the array of components within their membranous confines can not only provide insight...
Preclinical PET imaging in studies of candidate therapeutics
Jun 22, 2017
Clinical and preclinical non-invasive PET imaging is employed in the development and validation of therapeutic agents for cancer and neurological disorders, and a range of other diseases. Reported studies have used numerous agents including FDG, FLT, FMISO and FAZA as early biomarkers of drug efficacy. Preclinical PET imaging has been proven in studies of therapeutic targeting and biodistribution, drug target interactions, pharmacodynamics and toxicology. These methods have helped facilitate the development of therapeutic agents that are now clinically available. Probably two of the most common uses of preclinical PET imaging in drug discovery are studies of compound targeting and biodistribution and therapeutic efficacy. In the article, you can find a brief introduction to preclinical PET imaging for such studies.
Brand profile
